Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 11.05.2025 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Clin Pathol 1 Am J Respir Crit Care Med 2 Ann Surg Oncol 3 Ann Thorac Surg 4 BMC Cancer 2 Cancer 1 Cancer Res 1 Carcinogenesis 2 Clin Lung Cancer 1 Clin Nucl Med 2 Eur J Cardiothorac Surg 1 J Clin Oncol 1 J Natl Cancer Inst 3 J Thorac Cardiovasc Surg 1 J Thorac Oncol 1 JAMA Oncol 2 Lung Cancer 1 Oncogene 2 Oncologist 1 PLoS Comput Biol 4 PLoS One 1 Proc Natl Acad Sci U S A 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. AHN Y, Lee SM, Choe J, Choi S, et al
   Prognostic Implications of the Volume Doubling Time of the Solid Component in Lung Adenocarcinomas Manifesting as Part-Solid Lesions on Chest CT.
   AJR Am J Roentgenol. 2025 Feb 12. doi: 10.2214/AJR.24.32470.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

2. GILMORE LA, Willmann J, Olaechea S, Gilmore BW, et al
   Prevalence and Development of Cachexia Before and After Diagnosis of Non-small Cell Lung Cancer.
   Am J Clin Oncol. 2025 May 5. doi: 10.1097/COC.0000000000001211.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

3. HOGARTH NC, Al-Kawaaz M, Linder MW
   Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer.
   Am J Clin Pathol. 2025 May 7:aqaf038. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Am J Respir Crit Care Med

4. MADRIGAL JM, Fisher JA, Pruitt CN, Liao LM, et al
   Carcinogenic Industrial Air Emissions and Lung Cancer Risk in a Cohort of 440,000 Americans.
   Am J Respir Crit Care Med. 2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. HASHINOKUCHI A, Kinoshita F, Iimori M, Kosai K, et al
   DNA Polymerase Delta 2 Activates Cell Cycle in Lung Adenocarcinoma, Leading to High Malignancy and Poor Prognosis.
   Ann Surg Oncol. 2025;32:4487-4496.
   PubMed         Abstract available
   
   
6. SINGH A, Xie Y, Mazzola E, Wang S, et al
   Gait Speed as a Measure of Frailty and Outcomes After Lung Resection.
   Ann Surg Oncol. 2025;32:4181-4188.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

7. DING H, Tao B, Xu L, Jiang G, et al
   Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer with Mutations Beyond EGFR 19del, L858R, and ALK rearrangement.
   Ann Thorac Surg. 2025 May 6:S0003-4975(25)00378.
   PubMed         Abstract available
   
   
8. KHAN AA, Shah SK, Naeem W, Ansari M, et al
   Association Between Social Vulnerability Index and Time-to-Treatment in Resectable Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2025 May 6:S0003-4975(25)00380.
   PubMed         Abstract available
   
   
9. LAM GT
   Medicaid Expansion and Regionalization of Lung Cancer Surgery: A Double-Edged Sword?
   Ann Thorac Surg. 2025 May 2:S0003-4975(25)00374.
   PubMed        
   
   

   
   BMC Cancer

10. ZHAO S, Du X, Zhang Y, Bai J, et al
    Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens.
    BMC Cancer. 2025;25:842.
    PubMed         Abstract available
    
    
11. ZHANG J, Zhang Z, Liu Y, Hou Y, et al
    Metabolic characteristics of benign and malignant pulmonary nodules and establishment of invasive lung adenocarcinoma model by high-resolution mass spectrometry.
    BMC Cancer. 2025;25:844.
    PubMed         Abstract available
    
    
12. ZHAO F, Bai H, Liu Y, Gao S, et al
    FLT3LG modulates the infiltration of immune cells and enhances the efficacy of anti-PD-1 therapy in lung adenocarcinoma.
    BMC Cancer. 2025;25:831.
    PubMed         Abstract available
    
    
13. DONG J, Qi Y, Sha S, Fu C, et al
    Whole-body CT scanning radiation improves the immune microenvironment of tumor tissues to enhance the antitumor effect of ICI.
    BMC Cancer. 2025;25:824.
    PubMed         Abstract available
    
    

    
    Cancer

14. KILICKAP S, Ozguroglu M, Sezer A, Gumus M, et al
    Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 >/=50.
    Cancer. 2025;131:e35864.
    PubMed         Abstract available
    
    
15. DENNEHY C, Conroy MR, Forde PM
    Immunotherapy for resectable lung cancer.
    Cancer. 2025;131:e35849.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. THOMAS-JARDIN S, Suresh S, Arce A, Novaresi N, et al
    The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.
    Cancer Res. 2025 May 6. doi: 10.1158/0008-5472.CAN-24-3844.
    PubMed         Abstract available
    
    

    
    Carcinogenesis

17. PAN C, Zhou Z, Cao J, Zhang L, et al
    MACC1 is a potential prognostic biomarker for cancer immunotherapy in lung adenocarcinoma.
    Carcinogenesis. 2025;46:bgaf015.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

18. MA R, Yang H, Ge Y, Ma T, et al
    Prognostic Implications of Lymph Node Status in Non-Small-Cell Lung Cancer Patients Before and After Neoadjuvant Chemoimmunotherapy: A Multicenter Retrospective Study.
    Clin Lung Cancer. 2025 Apr 8:S1525-7304(25)00062.
    PubMed         Abstract available
    
    
19. ODWUOR A, Lee P, Chang JY, Gandhi S, et al
    Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2025 Apr 10:S1525-7304(25)00060.
    PubMed         Abstract available
    
    

    
    Clin Nucl Med

20. WANG R, Chen J, Wang J, Zhu Z, et al
    Primary Pulmonary MALT Lymphoma on 18F-FDG and 68Ga-FAPI PET/CT.
    Clin Nucl Med. 2025 Jan 20. doi: 10.1097/RLU.0000000000005687.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

21. AGUINAGALDE B, Lizarbe IA, Rumbero JC, Lorenzo M, et al
    Is histological confirmation necessary to avoid futile resections? Comparative of 4 university hospitals.
    Eur J Cardiothorac Surg. 2024;65:ezae136.
    PubMed         Abstract available
    
    
22. ARNARSSON LB, Stenger M
    Lymph node sampling and survival in non-small cell lung cancer: A 10-year Danish cohort study.
    Eur J Cardiothorac Surg. 2025 May 8:ezaf158. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. HUANG DD, Yang JC
    Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
    J Clin Oncol. 2025 May 8:JCO2500997. doi: 10.1200/JCO-25-00997.
    PubMed        
    
    

    
    J Natl Cancer Inst

24. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

25. BASKIN AS, Funk EC, Francescatti AB, Sinco BR, et al
    Early Compliance with Lung Cancer Lymph Node Standard 5.8: An Analysis of 2022 and 2023 Commission on Cancer Site Reviews.
    J Thorac Cardiovasc Surg. 2025 Apr 29:S0022-5223(25)00340.
    PubMed         Abstract available
    
    
26. WILLIAMS JE, Jacobs RC, Savitch SL, Hollenbeck ME, et al
    Provider and Procedural Factors Associated with Guideline-Concordant Lymph Node Sampling in Lung Cancer Resection.
    J Thorac Cardiovasc Surg. 2025 Apr 17:S0022-5223(25)00304.
    PubMed         Abstract available
    
    
27. LI H, Pezeshkian F, Xie Y, Mazzola E, et al
    Lung Cancer Recurrence after Neoadjuvant Immunotherapy.
    J Thorac Cardiovasc Surg. 2025 Apr 20:S0022-5223(25)00328.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

28. SABARI JK, Yu HA, Mahadevia PJ, Liu Y, et al
    Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States.
    J Thorac Oncol. 2025 May 2:S1556-0864(25)00699.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

29. HEYWARD J, Lesko CR, Murray JC, Mehta HB, et al
    Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2025 May 8. doi: 10.1001/jamaoncol.2025.0985.
    PubMed         Abstract available
    
    

    
    Lung Cancer

30. SHIRAI Y, Shukuya T, Asao T, Takahashi K, et al
    Epidemiology and clinical course of large cell neuroendocrine carcinoma of the lung: The Japanese lung cancer registry study.
    Lung Cancer. 2025;204:108557.
    PubMed         Abstract available
    
    
31. NGUYEN MH, Le MHN, Bui AT, Le NQK, et al
    Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis.
    Lung Cancer. 2025;204:108577.
    PubMed         Abstract available
    
    

    
    Oncogene

32. ZHANG C, Zhou W, Xu H, Xu J, et al
    Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.
    Oncogene. 2025;44:1400-1414.
    PubMed         Abstract available
    
    

    
    Oncologist

33. GIRARD N, Xu Q, Camidge DR, Baijal S, et al
    Real-world treatment and outcomes for EGFR WT advanced/metastatic non-squamous non-small cell lung cancer: pooled analysis from project LUMINATE-101.
    Oncologist. 2025;30:oyaf029.
    PubMed         Abstract available
    
    
34. LIN VTG, Ma E, Jain N, Xia Z, et al
    A rising tide lifts all boats in the personalized cancer care continuum for mNSCLC: bridging inequities in NGS fosters equity in targeted treatment.
    Oncologist. 2025;30:oyaf067.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

35. NOURBAKHSH M, Zheng Y, Noor H, Chen H, et al
    Revealing cancer driver genes through integrative transcriptomic and epigenomic analyses with Moonlight.
    PLoS Comput Biol. 2025;21:e1012999.
    PubMed         Abstract available
    
    

    
    PLoS One

36. DE-TORRES JP, Giron-Flamenco JJ, Rodriguez M, de la Fuente-Ano A, et al
    Exploring the impact of surgical treatment for lung cancer in patients with Airway Obstruction from a Lung Cancer Screening Program.
    PLoS One. 2025;20:e0320704.
    PubMed         Abstract available
    
    
37. OTERO-CARRASCO B, Nevado PT, Munoz RA, Ferreiro GD, et al
    Finding patterns in lung cancer protein sequences for drug repurposing.
    PLoS One. 2025;20:e0322546.
    PubMed         Abstract available
    
    
38. RAO S, Wu H, Zhang G, Dong W, et al
    A comparative analysis of the burden, trends and inequalities of tracheal, bronchus, and lung cancer in India from 2000 to 2021: A systematic analysis for the Global Burden of Disease study 2021.
    PLoS One. 2025;20:e0322646.
    PubMed         Abstract available
    
    
39. SALOMONSSON A, Ehinger D, Jonsson M, Botling J, et al
    Gene expression-based identification of prognostic markers in lung adenocarcinoma.
    PLoS One. 2025;20:e0310232.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

40. JIAO Z, Zhang M, Ning J, Yao H, et al
    The oncoprotein SET promotes serine-derived one-carbon metabolism by regulating SHMT2 enzymatic activity.
    Proc Natl Acad Sci U S A. 2025;122:e2412854122.
    PubMed         Abstract available
    
    

    
    Semin Oncol

41. ZHENG M
    High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy.
    Semin Oncol. 2025;52:152334.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.